Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.

Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, Coccheri S.

Stroke. 1997 May;28(5):1015-21.


Indobufen: an updated review of its use in the management of atherothrombosis.

Bhana N, McClellan KJ.

Drugs Aging. 2001;18(5):369-88. Review.


[Italian Study on Atrial Fibrillation (SIFA): status report].

Amabile G, Matteoli S, Fattapposta F, Lavezzari M, Trappolini M, Heiman F, Morocutti C.

Cardiologia. 1993 Dec;38(12 Suppl 1):327-32. Italian.


Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.

Taylor FC, Cohen H, Ebrahim S.

BMJ. 2001 Feb 10;322(7282):321-6. Erratum in: BMJ. 2001 Mar 10;322(7286):587.


[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].

[No authors listed]

G Chir. 1995 Mar;16(3):137-9. Italian. No abstract available.


Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.

Fornaro G, Rossi P, Mantica PG, Caccia ME, Aralda D, Lavezzari M, Pamparana F, Milanesi G.

Circulation. 1993 Jan;87(1):162-4.


Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation.

Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, John N, Noventa F, Dalla Volta S.

Am J Cardiol. 1998 Aug 15;82(4):433-7.


[Thromboembolism in non-rheumatic atrial fibrillation].

Pengo V.

Haematologica. 2001 Sep;86(9 Suppl):5-11. Review. Italian. No abstract available.


Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators.

JAMA. 2005 Feb 9;293(6):690-8.


Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

[No authors listed]

Arch Intern Med. 1994 Jul 11;154(13):1449-57. Erratum in: Arch Intern Med 1994 Oct 10;154(19):2254.


Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.

Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.


Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators.

Am Heart J. 2006 Nov;152(5):967-73.


Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.


[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin].

Hu DY, Zhang HP, Sun YH, Jiang LQ; Antithrombotic Therapy in Atrial Fibrillation Study Group.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Apr;34(4):295-8. Chinese.


Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.

van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, Schutgens RE, Klijn CJ; APACHE-AF Investigators.

Trials. 2015 Sep 4;16:393. doi: 10.1186/s13063-015-0898-4.


Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.

Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A.

Circulation. 2014 Jun 24;129(25):2638-44. doi: 10.1161/CIRCULATIONAHA.113.006426. Epub 2014 Apr 17.


Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.

Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE.

J Thromb Haemost. 2014 Jun;12(6):824-30. doi: 10.1111/jth.12546.

Supplemental Content

Support Center